- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02262364
Safety of NStride Autologous Protein Solution in the Treatment of Knee Osteoarthritis (PROGRESS I)
A Pilot Study of a Single Intra-articular Injection of Autologous Protein Solution in Patients With Knee Osteoarthritis
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Indiana
-
Elkhart, Indiana, United States, 46550
- Orthopedic and Sports Medicine Center of Northern Indiana (OSMC)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female ≥40 and ≤75 years old at time of injection..
- A standing radiograph of the knee showing a Kellgren-Lawrence grade of 2 to 4 (within 6 months of screening).
- Body mass index ≤40 kg/m2.
- A Western Ontario and McMaster Universities osteoarthritis index using the Likert scale, Version 3. (WOMAC LK 3.1) pain subscale total score ≥ 10 and ≤ 19.
- Has undergone at least two prior conservative OA therapies without satisfactory pain relief.
- Patient has failed to get satisfactory pain relief from either HA or steroid injections or would be considered an appropriate patient to receive either HA or steroid injections
Exclusion Criteria:
- Presence of active infection or abnormal effusion in the knee immediately preceding treatment injection.
- Presence of symptomatic OA in the non-study knee
- Diagnosed with rheumatoid arthritis, Reiter's syndrome, psoriatic arthritis, gout, ankylosing spondylitis, chondromalacia, arthritis secondary to other inflammatory diseases, or of metabolic origin; HIV, viral hepatitis; chondrocalcinosis, Paget's disease, villonodular synovitis, and other non-OA joint disease.
- Disease of spine, hip or other lower extremity joints of sufficient degree to affect assessment of the index knee
- Untreated symptomatic injury of index knee (e.g., acute traumatic injury, anterior cruciate ligament injury, meniscus injury, cartilage lesion).
- Knee radiographs showing bone-on-bone or other gross cartilage deficits.
- Presence of surgical hardware or other foreign body in the index knee.
- Intra-articular steroid injections in the index knee within 3 months of screening.
- Intra-articular HA in the index knee within 6 months of screening.
- Other intra-articular therapy in the index knee within 6 months prior to screening.
- Systemic steroid use within 2 weeks of screening.
- Planned/anticipated surgery of the index knee during the study period.
- A history of local anesthetic allergy
- Use of systemic immunosuppressants within six weeks of treatment.
- Currently on anticoagulant therapy
- Any documented clinically significant condition (e.g., diabetes, malignancy), finding, or psychiatric illness at screening which could compromise patient safety or interfere with the assessment of the safety and treatment effects of the study injection.
- Skin breakdown at the index knee where the injection is planned to take place.
- Pregnant or nursing mothers or women who are planning on getting pregnant during the time they will be participating in the study.
- Known drug or alcohol dependence currently or within the last year.
- Used any investigational drug or device within 30 days prior to screening.
- Used any investigational biologic within 60 days prior to screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NStride APS
Subjects will receive an intra-articular injection of APS.
|
See above
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: 1 Year
|
Adverse Events and Serious Adverse Events
|
1 Year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline to 12 Months in Pain, Stiffness, and Function in Daily Living Measured With WOMAC Questionnaire
Time Frame: 12 months
|
The WOMAC LK 3.1 questionnaire is a validated tool commonly used for assessing knee pain, stiffness, and function. The WOMAC LK 3.1 questionnaire has 24 items that the patient addresses about the knee: 5 items on the pain subscale, 2 on the stiffness subscale, and 17 on the physical function subscale. Each item is answered on a 5-point Likert scale, with grading from 0 (none or never) to 4 (extreme or always). A higher score indicates worse pain, stiffness, or functional limitation. The WOMAC pain subscale consists of five questions scored from 0 to 4. The pain score has a range of 0 (no pain) to 20 (maximal pain). The WOMAC stiffness subscale consists of two questions scored from 0 to 4. The stiffness score has a range of 0 (no stiffness) to 8 (maximal stiffness). The WOMAC physical function subscale consists of seventeen questions scored from 0 to 4. The physical function score has a range of 0 (no functional limitation) to 68 (maximal functional limitation). |
12 months
|
Change From Baseline to 12 Months in Pain as Measured by the Numeric Rating Scale (NRS)
Time Frame: 12 months
|
The Numeric Rating Scale (NRS) is a validated measure of knee pain.
The NRS is an 11 point Likert type scale anchored by 0 "no pain" and 10 "worst possible pain".
Subjects rate their average pain over the last 24 hours.
|
12 months
|
Change From Baseline to 12 Months in Pain as Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS)
Time Frame: 12 months
|
The KOOS questionnaire is a commonly used instrument to assess the patient's opinion about their knee and associated problems. KOOS consists of 5 subscales: Pain (9 questions), Symptoms (7 questions), Function in daily living (ADL) (17 questions), Function in sport and recreation (Sport/Rec) (5 questions) and knee related Quality of Life (QOL) (4 questions). The previous week is used as the time period for answering the questions. A higher score on the KOOS questionnaire indicates fewer problems, and 0 indicates extreme problems. Each subscale score is calculated independently. The mean score of the individual items of each subscale is calculated and divided by 4 (the highest possible score for a single answer option). Traditionally in orthopedics, 100 indicates no problems and 0 indicates extreme problems. The normalized score is transformed to meet this standard. |
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mark Klaassen, OSMC
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- APSS-22-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis, Knee
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Novartis PharmaceuticalsRecruitingSymptomatic Knee OsteoarthritisUnited States, Spain, Hungary, Argentina, Germany, Slovakia, Czechia, Belgium, Romania
-
University of BathUniversity of Oxford; 3D Metal Printing Ltd; Versus ArthritisRecruitingMedial Knee OsteoarthritisUnited Kingdom
-
Max Biocare Pty. Ltd.Completed
Clinical Trials on APS
-
University of WashingtonNational Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaboratorsCompleted
-
The University of Texas Health Science Center,...The Center for Clinical and Translational Sciences (CCTS) Clinical Research...CompletedCognitive Ability, General | Geriatric Disorder | Self-NeglectUnited States
-
Mayo ClinicMedtronicTerminatedParotid Gland DisordersUnited States
-
Zimmer BiometCompletedOsteoarthritis, KneeUnited Kingdom
-
Zimmer BiometCompletedOsteoarthritis, KneeItaly, Austria, Belgium, Norway
-
Johann Wolfgang Goethe University HospitalCompleted
-
Northern Orthopaedic Division, DenmarkCompleted
-
University of Wisconsin, MadisonCompleted
-
Ditte Gertz MogensenRecruiting
-
The University of Texas Health Science Center,...US Department of Health and Human Services, Administration on Community LivingRecruitingDepression in Old AgeUnited States